News

The NDA was based on an international, randomized, multicenter, double-blind, relapse prevention Phase III trial of paliperidone palmitate three-month injection. More than 500 patients were included in the

NHPN-1010 is being developed to treat noise-induced hearing loss (NIHL) and Cisplatin-induced hearing loss (CIHL). The Phase I trial will determine the safety, tolerability and pharmacokinetic (PK) profile

As part of the deal, Sunshine will manufacture Adva-27a using Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients. The Swiss firm’s manufacturing

The MPNs include essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). A total of 18 patients have been enrolled in this open-label, single-arm, multicenter Phase II

According to FDA, all currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols. Additionally, the company cannot enrol new patients until the

The new liquid formulation eliminates the need of reconstituting lyophilized powder with sterile water before adding the required dose of medicine to the infusion bag and administering to

Created by Atlas Venture and Caribou Biosciences, together with leading scientists who have pioneered and shaped the field of CRISPR biology, Intellia leverages exclusive access to one of

The collaboration will focus on new therapeutic approaches for the treatment of various acute neurological conditions resulting from neurovascular instability. This discovery collaboration brings together Edge’s scientific expertise

"We are proud and hopeful to play a role to develop a treatment that could potentially reduce the rate of prosthesis abandonment for those who have so honorably